Hsp90/Cdc37 Chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A by Grover, Abhinav et al.
RESEARCH Open Access
Hsp90/Cdc37 Chaperone/co-chaperone complex,
a novel junction anticancer target elucidated by
the mode of action of herbal drug Withaferin A
Abhinav Grover
1, Ashutosh Shandilya
2, Vibhuti Agrawal
1, Piyush Pratik
1, Divya Bhasme
1,
Virendra S Bisaria
1, Durai Sundar
1*
From The Ninth Asia Pacific Bioinformatics Conference (APBC 2011)
Inchon, Korea. 11-14 January 2011
Abstract
Background: HSPs (Heat shock proteins) are highly conserved ubiquitous proteins among species which are
involved in maintaining appropriate folding and conformation of other proteins and are thus referred to as
molecular chaperones. Hsp90 (Heat-shock protein 90 kDa) is one of a group of molecular chaperones responsible
for managing protein folding and quality control in cell environment. However it is also involved in the maturation
and stabilization of a wide range of oncogenic client proteins which are crucial for oncogenesis and malignant
progression. Hsp90 requires a series of co-chaperones to assemble into a super-chaperone complex for its function.
These co-chaperones bind and leave the complex at various stages to regulate the chaperoning process. Arresting
the chaperone cycle at these stages by targeting different co-chaperone/Hsp90 interactions seems to be quite a
viable alternative and is likely to achieve similar consequences as that of Hsp90 direct inhibition with added favors
of high specificity and reduced side effect profile. The study conducted here is an attempt to explore the potential
of Withania somnifera’s major constituent WA (Withaferin A) in attenuating the Hsp90/Cdc37 chaperone/
co-chaperone interactions for enhanced tumor arresting activity and to elucidate the underlying mode of action
using computational approaches.
Results: Formation of active Hsp90/Cdc37 complex is one of the essential steps for facilitation of chaperone client
interaction, non-assembly of which can lead to prevention of the chaperone-client association resulting in
apoptosis of tumor cells. From our flexible docking analysis of WA into active Hsp90/Cdc37 complex in which key
interfacing residues of the complex were kept flexible, disruption of the active association complex can be
discerned. While docking of WA into segregated Hsp90 leaves the interface residues untouched. Thus the
molecular docking analysis of WA into Hsp90 and active Hsp90/Cdc37 complex conducted in this study provides
significant evidence in support of the proposed mechanism of chaperone assembly suppression by inhibition or
disruption of active Hsp90/Cdc37 complex formation being accounted by non-assembly of the catalytically active
Hsp90/Cdc37 complex. Results from the molecular dynamics simulations in water show that the trajectories of the
protein complexed with ligand WA are stable over a considerably long time period of 4 ns, with the energies of
the complex being lowered in comparison to the un-docked association complex, suggesting the thermodynamic
stability of WA complexed Hsp90/Cdc37.
Conclusions: The molecular chaperone Hsp90 has been a promising target for cancer therapy. Cancer is a disease
marked by genetic instability. Thus specific inhibition of individual proteins or signalling pathways holds a great
potential for subversion of this genetic plasticity of cancers. This study is a step forward in this direction.
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any medium, provided the original work is properly cited.Our computational analysis provided a rationalization to the ability of naturally occurring WA to alter the
chaperone signalling pathway. The large value of binding energy involved in binding of WA to the active Hsp90/
Cdc37 complex consolidates the thermodynamic stability of the binding. Our docking results obtained substantiate
the hypothesis that WA has the potential to inhibit the association of chaperone (Hsp90) to its co-chaperone
(Cdc37) by disrupting the stability of attachment of Hsp90 to Cdc37. Conclusively our results strongly suggest that
withaferin A is a potent anticancer agent as ascertained by its potent Hsp90-client modulating capability.
Background
Heat shock proteins (HSPs) are highly conserved ubiqui-
tous proteins among species which are involved in
maintaining appropriate folding and conformation of
other proteins and are thus referred to as molecular
chaperones [1]. Hsp90 (90 kDa heat-shock protein) is
one of a group of molecular chaperones responsible for
managing protein folding and quality control in cell
environment [2]. It is one of the most abundant proteins
in the eukaryotic cells comprising 1-2% of total proteins
under non-stress conditions [3]. Although Hsp90 is
involved in assisting protein folding and preventing
aggregation of non-native proteins, it also plays a key
role under normal conditions in regulating the stability
and activation state of more than 200 ‘client’ proteins
molecules including transmembrane tyrosine kinasesta-
stable signaling proteins (Akt, Raf-1 and IKK), mutated
signaling proteins (p53, Kit, Flt3 and v-src), chimeric
signaling proteins (NPM–ALK, Bcr–Abl), steroid recep-
tors (androgen, estrogen and progesterone receptors)
and cell-cycle regulators (cdk4, cdk6) [4]. Recent sys-
tems-biology studies indicate that Hsp90 is a major
interaction node, regulating a very diverse set of cellular
functions [5-7].
Hsp90 as a therapeutic target in cancer
Hsp90 is involved in the maturation and stabilization of
a wide range of oncogenic client proteins which are cru-
cial for oncogenesis and malignant progression [8], the
cancer cells being particularly dependent on proper
Hsp90 function [9,10]. Many of these client proteins are
mutated and/or overexpressed in cancers [11]. More-
over, the harsh environmental conditions found in
tumors such as hypoxia, low pH, and bad nutritional
status may tend to destabilize proteins, making them
even more dependent on Hsp90 activity [8,12,13]. It has
been observed that Hsp90 is constitutively expressed at
manifold levels in tumor cells compared to their normal
counterparts [14], suggesting that Hsp90 is critically
important for tumor cell growth and and/or survival
and its inhibition would help check the proliferation of
cancer cells. Inhibition of Hsp90 would lead to the pro-
teasomal degradation of a large number of oncogenic
client proteins, offering an additional favour of combina-
torial impact on multiple oncogenic pathways and
amelioration of all the cancer attributing traits, including
proliferation, evasion of apoptosis, immortalization,
invasion, angiogenesis and metastasis [9]. In addition,
this combinatorial action markedly reduces the opportu-
nities for cancer cells to develop resistance to Hsp90
inhibition [15]. The association of Hsp90 with a plethora
of pathways including signal transduction, cell-cycle
control, transcriptional regulation and many others
[16-18] marks it as target for pharmacological modula-
tion in a number of diseases, particularly for cancer,
where the chaperoning of mutated and overexpressed
oncoproteins is critical [19]. This has led to the develop-
ment of Hsp90 inhibitors for treatment of human can-
cers [4,20].
Development of Hsp90 inhibitors
Chaperoning of Hsp90 client proteins is regulated
through a dynamic cycle driven by ATP binding to
Hsp90 and subsequent hydrolysis [21]. Thus blocking of
ATP binding has developed as a single well known
mechanism for development of Hsp90 inhibitors. The
currently established natural product inhibitors of
Hsp90 like radicicol, benzoquinone ansamycins like gel-
danamycin and its derivative 17-allylamino geldanamy-
cin, which are all based on the same ATP blocking
criterion, cause the catalytic cycle of Hsp90 to arrest in
the ADP-bound conformation, leading to the inactiva-
tion of chaperone activity, premature ubiquitination and
of client proteins [22,23]. The proteasomal degradation
of the client proteins finally result in depletion of onco-
proteins, cell cycle arrest and consequent apoptosis [24].
Though blockade of ATP binding seems to be the most
direct and the simplest way to inhibit Hsp90 function,
the intrinsic non-selectivity of this method for Hsp90
clientele limits its further application [25]. Of all the
inhibitors employing ATP blockage mechanism for
Hsp90 inhibition, none has received the Food and Drug
Administration approval [26], providing space for
exploration of alternative inhibition mechanisms.
Blocking of co-chaperone/chaperone interactions
It has been well reported that Hsp90 requires a series of
co-chaperones to assemble into a super-chaperone com-
plex for its function. These co-chaperones bind and
leave the complex at various stages to regulate the
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at these stages by targeting different co-chaperone/
Hsp90 interactions seems to be quite a viable alternative
and is likely to achieve similar consequences as that of
Hsp90 direct inhibition [26,27]. Cdc37 (Cell division
cycle protein 37), one of the essential co-chaperone of
Hsp90, plays a specialized and indispensable role in the
maturation of a number of kinase clients, whose func-
tions are commonly dysregulated in cancer, such as
receptor tyrosine kinases like epidermal growth factor
receptor (EGFR), non-receptor tyrosine kinases Src and
lymphocyte specific protein tyrosine kinase (Lck), and
intracellular serine/threonine kinases such as Raf-1and
Cdk4 [28]. Cdc37 facilitates the maturation of these
kinase clients by acting as an adaptor, loading these
kinases onto the Hsp90 complex [29-31]. Knocking out
of Cdc37 using RNAi has been shown to attenuate the
kinase clients’ association to Hsp90 in human colon
cancer cells, leading to reduced cell proliferation.
Furthermore, combining Cdc37 silencing with the
HSP90 inhibitor 17-AAG induced more extensive and
sustained depletion of kinase clients and potentiated cell
cycle arrest and apoptosis. These results support an
essential role for Cdc37 in concert with Hsp90 in main-
taining oncogenic protein kinase clients and endorse the
therapeutic potential of targeting Cdc37/Hsp90 in can-
cer [32].
Targeting Cdc37/Hsp90 interaction represents a poten-
tial alternative to direct Hsp90 inhibition that may offer
greater specificity (due to Cdc37 elevated expression in
cancer) and an improved side effect profile [27]. Addi-
tionally, Cdc37 may be an attractive target in tumor
types such as androgen independent prostate cancers
that currently lack highly effective therapies. Recently,
Celastrol, a quinone methide triterpene from Triptery-
gium wilfordii , has been shown to exhibit anti-pancreatic
cancer activity both in vitro and in vivo through the dis-
ruption of Cdc37/Hsp90 association and the subsequent
degradation of Hsp90 client proteins [26].
Withania somnifera,a l s ok n o w na s“ashwagandha”,
“Queen of Ayurveda”, “Indian ginseng”,a n d“winter
cherry”, has been an important herb in the Ayurvedic
and indigenous medical systems for more than
3,000 years [33]. Its roots have been used as herb
remedy to treat a variety of ailments and to promote
general wellness. It has received much attention in
recent years due to the presence of a large number of
alkaloids and steroidal lactones known as withanolides
[34,35]. The structure of basic skeleton of withanolides
is shown in Figure 1. The principal withanolide present
in the plant is WA which is known to have anti-
inflammatory [36], antitumor [37], antibacterial [38],
antioxidant [39], anticonvulsive [40], and immunosup-
pressive properties [41]. It has the potential to increase
tumor sensitization to radiation and chemotherapy
while reducing some of the most common side effects
of these conventional therapies [42]. Most recently,
WA has been shown to potentiate apoptosis of tumor
cells by inhibiting Hsp90 in human pancreatic cancer
cells [43], protect against UV-induced skin cancer [44]
and enhance neurite regeneration and memory [45,46].
Thus, many studies have been reported depicting the
effect of WA on putting a check on human cancers,
but the mechanism behind this effect is still eluding
the researchers. The study conducted here is an
attempt to explore the potential of Withania somni-
fera’s major constituent WA in attenuating the Hsp90/
Cdc37 chaperone/co-chaperone interactions for
enhanced tumor arresting activity and to elucidate the
underlying mode of action using computational
approaches.
Figure 1 Structures of withanolides. (A) Withaferin A falls under
the family of compounds known as withanolides which are a group
of naturally occurring C28- steroidal lactones built on an intact or
rearranged ergostane framework, in which C-22 and C- 26 are
appropriately oxidized to form a six-membered lactone ring. The
basic structure is designated as the withanolide skeleton defined as
a 22-hydroxyergostan-26-oic acid-26,22-lactone. (B) Structure of
withaferin A.
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Ligand and Receptors
The crystal structure of the Hsp90/Cdc37 association
domain [PDB: 2K5B] was obtained from the Protein
Data Bank (PDB) [47]. The crystal structure contained
many missing atoms which were supplemented by the
repairCommands module of AutoDock. Before docking,
the protein crystal structure was cleaned by removing
the water molecules. H-atoms were added to these tar-
get proteins for correct ionization and tautomeric states
of amino acid residues. The modified structure so
obtained was used for all the flexible docking studies
while only Hsp90 [PDB: 3HZ5] was used for performing
semi-flexible dockings. The ligand molecule withaferin
A [PubChem:265237] was retrieved from NCBI-
PubChem Compound database [48]. The structure of
this compound is shown in Figure 1. The energy of the
ligand molecule and receptors were minimized in Stee-
pest Descent and Conjugate Gradient methods using
Amber 11 [49], the most comprehensive suite for carry-
ing molecular dynamics simulations.
Structural aspects of Cdc37-Hsp90 complex
Hsp90 is composed of three domains: an N-terminal
domain of ~25-kDa, a middle domain of ~35-kDa, and
a C-terminal domain of ~10-kDa [50]. The ATP-binding
site of Hsp90 is located in the N-terminal domain.
The 44.5-kDa Cdc37 protein can be dissected into
three domains [51,52] : an N-terminal domain (residues
1-127 (Cdc37N), 15.5 kDa), a middle domain (residues
147-276 (Cdc37M) 16 kDa), and a C-terminal domain
(residues 283-378 (Cdc37C), 10.5 kDa). The middle
domain Cdc37M is highly resistant to proteolytic diges-
t i o na n dw a sf o u n dt ob et h em o s ts t a b l ed o m a i no f
Cdc37 [53]. The Hsp90 binding site is located in the
middle domain of Cdc37 which associates with the
Nterminal domain of Hsp90 [54,55]. The structural fea-
tures of the receptor macromolecule [PDB: 2K5B] have
been described in detail elsewhere [47] by the depositors
of the crystal structure to the Protein Data Bank. Briefly,
the receptor is an association complex of Cdc37M and
Hsp90N in respectively two chains. Hsp90N density
extends from residues Glu 14 to Glu 223 in chain A
and the Cdc37M peptide density extends from residues
Lys 148 to His 276 in chain B. The Cdc37 peptides are
almost helical except for few unwound stretches ranging
from 164–168. For Hsp90, residues 117, 121, 123, 124,
125, 126, and 129 have been defined as active. For
Cdc37M, residues 160, 161, 164, 165, 166, 167, 168, 193,
202, 204, 205, and 208 have been defined as Active. The
Cdc37M residues that appear to be on the interface
region of the association complex include Lys-160, Met-
164, Arg-166, Arg-167, Trp-168, Leu-205, Glu-207, Gln-
208, and Ile-214. Electrostatic interactions are observed
between the residues Arg-166, Arg-167, and Asp-170 of
Cdc37M and Gln-133 of Hsp90N. Arg-166 and Arg-167
residues of Cdc37 peptide form intermolecular hydrogen
bonds with residue Gln-133 of Hsp90N. The hydropho-
bic core involves residues Met-164, Trp-193, Ala-204,
and Leu-205 of Cdc37M and Ala-117, Ala-121, Ala-124,
Ala-126, Met-130, and Phe-134 of Hsp90N.T h es i d e
chain of Glu-120 of human Hsp90 forms a hydrogen
bond with the Lys-202 side chain of Cdc37. An impor-
tant hydrogen bond is formed between Glu-47 of Hsp90
and Arg-167 of Cdc37, which is considered to be the
key interaction that arrests the ATPase action of Hsp90
[54]. It was also observed that the amino moiety of Gln
208 of Cdc37 is rather close to the side-chain hydroxyl
group of the Ser-113 residue of Hsp90, with which it
may possibly form an intermolecular hydrogen bond.
Semi-flexible docking
AutoDock 4.0 suite was used as molecular-docking tool
in order to carry out the docking simulations [56].
AutoDock has been found to be able to locate docking
modes that are consistent with X-ray crystal structures
[57,58]. AutoDock helps to simulate interactions
between substrates or drug candidates as ligands and
their macromolecular receptors of known three dimen-
sional structures, allowing ligand flexibility described to
a full extent elsewhere [56]. In our docking simulations
we first used only the human HSP90 X-ray crystal struc-
ture [PDB: 3HZ5] for performing semi-flexible docking,
w i t ht h el i g a n dW Am a d ef l e x i b l ew h i l ek e e p i n gt h e
receptor macromolecule being rigid. Flexibility of the
ligand helps it explore six spatial degrees of freedom for
rotation and translation and an arbitrary number of tor-
sional degrees of freedom. A random perturbation to
each is applied at each time step, and the interaction
energy was evaluated for the new location and confor-
mation [59].
Flexible docking
O n eo ft h en o v e lf e a t u r e so fA u t o D o c k4 . 0a l l o w ss i d e
chains in the protein as well as in the ligand to be flex-
ible. Thus flexibility of receptor molecule was also
exploited in docking studies by making use of AutoDock
flexres scripts. It is worth assumable that the incoming
ligand arriving at the binding sites of the two chains
would try to make its own associations with the residues
in order to minimize the energy of the system. To facili-
tate this notion, the key residues of Hsp90 and Cdc37
chains, majority of which form H-bonds with corre-
sponding residues in the two chains as reported [47],
were made flexible in order to observe their mode of
interactions with the ligand and to account for the
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amino acids chosen to be flexible were kept “inactive”
or non-rotatable. The Graphical User Interface program
“AutoDock Tools” was used to prepare, run, and analyze
the docking simulations. Protein was prepared for dock-
ing simulations by assigning of Kollman united atom
charges, solvation parameters and polar hydrogens to
the receptor PDB file. Water molecules were removed
from its PDB file to make it a free receptor. Since
ligands are not peptides, Gasteiger charge was assigned
and then nonpolar hydrogens were merged. AutoDock
assigns the rigid roots to the ligand automatically saving
time as compared to manual picking. Five bonds in the
ligand were made “active” or rotatable. Atomic solvation
parameters were assigned to the receptor using default
parameters.
Grid design
Auto-Tors, an auxiliary program using Interactive
queries to define rotatable torsion angles, is used to
assign all rotatable dihedrals in the ligands and to
remove non-polar hydrogen atoms, uniting their partial
charges with their bonded carbon atoms. AutoGrid,
which calculates grids of interaction energy based on
the interaction of the ligand atom probes with receptor
target, is used to obtain the grid maps required prior to
docking. Each probe consists of an atom type present in
the ligand being docked. The pre-calculated grid maps
store the potential energy arising from the interaction
with the macromolecule. The user defined three dimen-
sional grid must surround the region of interest in the
macromolecule, and the ligand was limited to this
search space during docking. In the present study, the
location and dimensions of the grid box are chosen
such that it incorporates the flexible residues which are
involved in binding of Cdc37 to Hsp90 for the forma-
tion of active complex. The energy scoring grid was
prepared as a 36, 30 and 40 A° (x, y, and z) cube for
semi-flexible docking and 60, 60, and 60 A° (x, y, and z)
cube for flexible docking. The spacing between grid
points was 0.375 angstroms.
The Genetic Algorithm
The Lamarckian Genetic Algorithm (LGA) was chosen
to search for the best conformers. Using mathematical
concepts designed to simulate the conditions influen-
cing biological evolution, genetic algorithms are able to
search conformational space by “mutating” a ligand in
order to find its lowest energy conformation in the
“environment” of a fixed protein. Searches driven by
this energy funnelling have been shown to provide a
good indication as to the optimum protein-ligand inter-
actions and therefore conveying the structure most
likely to be found in vivo [60]. The default parameters
for the Lamarckian genetic algorithm [56] were used as
the search protocol except for the maximum number of
energy evaluations, which were changed to 2.5 million.
During the docking process, a maximum of 10 confor-
mers was considered for each compound. The popula-
tion size was set to 150 and the individuals were
initialized randomly. Maximum number of generations
was kept as 15000, maximum number of top individuals
that automatically survived set to 1 with a mutation
rate of 0.02 and a crossover rate of 0.8. Step sizes for
translations, quaternions and torsions were kept same
as defaults. An efficient and accurate energy assessment
of the ligand conformations is as important to the suc-
cess of a docking simulation as the power of the search
algorithm. AutoDock uses a variation on the ‘95 force
field [49] with terms empirically determined by linear
regression analysis from a set of protein-ligand com-
plexes with known binding constants [56,61]. Gibbs
Free energy (ΔG) is calculated as a sum of six energy
terms of dispersion/repulsion, hydrogen bonding, elec-
trostatic interactions, deviation from covalent geometry,
internal ligand torsional constraints, and desolvation
effects.
Selection and representation of docking modes
AutoDock reports the best docking solution (lowest
docked free energy) for each GA run and also performs
a cluster analysis in which the total number of clusters
and the rank of each docking mode (cluster rank) are
reported. Docking modes were selected on the basis of
two criteria: ligand’s proximity to the Asp 166 of middle
Cdc37 chain and extent of the ligand’s associations with
the Cdc37-Hsp90 interacting residues. For a 10 GA run
there would be up to 10 total docking modes from
which the lowest energy-docking mode was chosen that
met the above two criteria. All the AutoDock docking
runs were performed in Intel Core 2 Duo P8400 CPU @
2.26 GHz of Sony origin, with 3 GB DDR RAM. Auto-
Dock 4.0 was compiled and run under Windows VISTA
operating system. The output from AutoDock and all
modeling studies as well as images were rendered with
PyMOL [62] and Accelerys ViewerLite 5.0. ViewerLite
was used to calculate the distances of hydrogen bonds
as measured between the hydrogen and its assumed
binding partner.
Confirmation of the docking results
The docking results obtained using AutoDock were also
confirmed using ParDOCK [63] , which is an all atom
energy based monte carlo docking protocol. Docking
using ParDOCK requires a reference complex (target
protein bound to a reference ligand) and a candidate
molecule along with specific mention of the centre of
mass of the cavity on which the ligand is to be docked.
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The AMBER v.11 package [64] was used to prepare the
protein and the ligand files as well as for the Molecular
Dynamics (MD) simulations. The binding complexes of
Hsp90/Cdc37/WA and Hsp90/WA obtained using Par-
DOCK, and the un-docked proteins simulated in this
study were neutralized by adding appropriate number of
sodium counter-ions and were solvated in a octahedron
box of TIP4PEW water with a 10 Å distance between
the protein surface and the box boundary [65]. The par-
tial atomic charges for the ligand were obtained using
“antechamber” [66] module of Amber.
The energy minimization and MD simulations of
Hsp90, Hsp90/Cdc37 and their complex with WA were
carried out with the aid of the SANDER module of the
AMBER 11 program. First of all, the simulated binding
complex was effected with a 750 step minimization using
the steepest descent algorithm followed by a 250 step
minimization using conjugate gradient to remove bad
steric contacts. Topology and parameter files for the pro-
tein were generated using “ff99SB” and for the drug using
“gaff” based on the atom types of the force field model
developed by Cornell et al [49]. Then the system was
equilibrated beginning with the protein atom restrained
simulations having 200 ps equilibration dynamics of the
solvent molecules at 300 K and a harmonic potential
with a 10 kcal/mol restraint force. Next step involved the
equilibration of the solute molecules with a fixed config-
uration of the solvent molecules in which the system was
slowly heated from T = 0 to 300 K in 60 intervals each
involving heating for a 5 K increase in 2.5 ps followed by
an equal time duration equilibration step. The entire sys-
tem was then equilibrated at 300 K for 200 ps before a
sufficiently long MD simulation (for 4 ns) at room tem-
perature. The MD simulations were performed with a
periodic boundary condition in the NPT ensemble at
T=298.15 K with Berendsen temperature coupling [67]
and constant pressure P=1 atm with isotropic molecule-
based scaling . The SHAKE algorithm [68] was applied to
fix all covalent bonds containing hydrogen atoms. We
used a time step of 2 fs and a nonbond-interaction cutoff
radius of 10 A°. The Particle Mesh Ewald (PME) method
[69] was used to treat long-range electrostatic interac-
tions. The coordinates of the trajectory was sampled
every 2.5 ps for analysis of the energy stabilization and
RMSD values of the protein as well as that of the com-
plex. MD simulations were performed on a 320 proces-
sors SUN Microsystems clusters at Supercomputing
Facility (SCFBio) at IIT Delhi.
Results and discussion
Semi-flexible docking of WA into H90
One possible mode of action which is proposed here
for WA to act as a chaperone function inhibitor is by
restriction/disintegration of the complex between
Hsp90 and Cdc37. In order to explore the possibility
of non-formation of the complex, we first carried out
molecular docking studies with only the Hsp90 protein
crystal structure. Before docking to be carried out, the
structures of receptor macromolecules were minimized
using Sander module of Amber. Macromolecular
receptors minimized using Steepest Descent and Con-
jugate Gradient methods had comparatively lower
potential energy values than those of the initial ones
and are thus utilized further for carrying out the dock-
ing studies. Figure 2A shows the docked ligand WA
into the selective HSP90 receptor. WA gets buried
inside the pocket of HSP90 as depicted by mesh repre-
s e n t a t i o ni nF i g u r e2 B .F o rt h i s particular configuration
the binding energy of WA with Hsp90 is -9.10 Kcal/
mol with an Inhibition constant of 214.73 nM (Table
1). The binding of WA to Hsp90 is characterized by
H-bonding between a termin a lh y d r o x y lg r o u po ft h e
ligand and the side chain carboxyl group of Asp 102.
The other terminal hydroxyl group of WA is also
involved in a weak H-bond with Asp 54 of Hsp90 (Fig-
ure 3A). The lengths of the two H-bonds formed are
3.78 and 5.71 Å. In the present docked structure, WA
is also forming van der waals interactions with Leu 48,
Asn 51, Asp 54, Ala 55, Leu 107, Ala 111, Val 136 and
Phe 138 of Hsp90 (Figure 3B). These non-covalent
interactions help stabilize the binding of the ligand
with the macromolecule by lowering the energy. How-
ever, no interaction of WA with the proposed Cdc37
interacting residues could be observed, as is evident
from Figure 4. These finding suggests that binding of
WA to Hsp90 could only provide a naive hinderance
to the attachment of Cdc37 to Hsp90, owing to the
presence of yet available Cdc37 interacting residues of
Hsp 90 upon WA binding. However, WA binding to
Hsp90 may result in the formation of a deformed com-
plex as the Hsp90/Cdc37 complex would not get
assembled to its catalytically active form.
Flexible docking of WA into active Hsp90/Cdc37 complex
Docking of WA performed on the catalytically active
human Hsp90/Cdc37 complex provided interesting
results. The binding of WA to the association complex
provides significant evidence in support of the pro-
posed mechanism of chaperone/co-chaperone activa-
tion suppression by inhibition or disruption of active
Hsp90/Cdc37 complex. Two clusters were obtained for
Genetic Algorithm run from generation of ten models.
Large negative binding energies were obtained for both
the clusters as is evident from Table 2. The lowest
binding energy (-13.95 Kcal/mol) was much lower
than that obtained obtained from binding of WA to
the segregated Hsp90 receptor. As shown in Figure 5,
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H-bond present in the active complex by itself hydro-
gen bonding with both Ser 133 . One of the ring car-
bonyl group of the ligand is involved in H-bonding
with Gln 208 also, which has been reported as one of
the critical residues in complex formation [47]. The
same ring lactone group forms H-bond with Arg 166
residue of Cdc 37. Arg 166 and Arg 167 residues of
Cdc37 are involved in hydrogen bonding with Gln 133
of Hsp90 in the original functional complex. Thus
Figure 2 Docking representations of Withaferin A. (A) Ligand docked into the Hsp90 receptor cavity (B) Docked Ligand inside the pocket of
Hsp90 receptor mesh.
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binding of WA to the interface of Hsp90/Cdc37 struc-
turally disrupts the active complex. The absence of
active chaperone/co-chaperone complex would prevent
catalysis of the conformational maturation of the
Hsp90 client proteins. This would ultimately lead to
degradation of Hsp90 clients thus arresting their nefar-
ious acts.
Table 1 Energies obtained after docking of withaferin A
into Hsp90
Property Quantity
Binding Energy -9.10 Kcal/mol
Inhibition constant 214.73 nM
Intermolecular energy -10.36 Kcal/mol
Total internal energy -0.11 Kcal/mol
Figure 3 Interactions of docked withaferin A with Hsp90 receptor. (A) H-Bond interactions of the docked ligand with Hsp90 residues.
(B) Docked withaferin A forming vdw interactions with the hydrophobic residues of Hsp90.
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active complex, with a majority of earlier reported
H-bond and hydrophobic interaction forming residues
kept flexible, clearly show that WA blocks the intermo-
lecular interactions between Hsp90 and Cdc37 at the
residues which are significantly involved in formation of
the active complex. The large value of binding energy
(-13.95 Kcal/mol) involved in binding of WA to the
complex consolidates the thermodynamic stability of the
binding. These results substantiate the hypothesis that
WA possess the potential to disarray the active complex
by disrupting the stability of attachment of Hsp90 and
Cdc37 chains, being accounted by hydrophobic and
H-bond interactions.
MD simulations in water
The Hsp90/Cdc37/WA protein-drug binding complex
with the binding energy of -9.68 kcal/mol obtained
using ParDOCK was used for carrying out MD simula-
tions. After the MD simulations, we calculated RMSDs
between Ca of Hsp90/ Cdc37/WA complex trajectories
recorded every 2.5 ps and Ca of Hsp90/Cdc37 associa-
tion complex PDB structure. The RMSDs for the
trajectories of Hsp90 complexed with WA were also cal-
culated using the protein’s X-ray structure as a refer-
ence. The results in Figure 6A show that the RMSD
trajectory of Hsp90/Cdc37/WA complex was less than
2.5 Å for the entire simulation and achieves a stationary
phase in the later length of the simulation. It was noted
that Hsp90/Cdc37/WA (complex) has an additional
entity WA owing to which the RMSD of the complex is
higher than the Hsp90/Cdc37 (protein) in the initial
stage (0-700 ps) of simulation. However, as the simula-
tion progresses, the ligand in association with the recep-
tor protein tries to make interactions with the solvent
molecules and thus stabilizes the associated structure;
thus resulting in lowering of the RMSD trajectory in
comparison to the protein. The trajectory for the total
energy was also consistent throughout the simulation
length. It was also found that the energy of the complex
(blue) was lower than that of the protein (red) alone
throughout the length of the simulation (Figure 6B),
suggesting the stability of our docked protein-drug sys-
tem. MD simulations were also carried out for Hsp90 in
complex with WA. The consistency of RMSD and
energy profiles of the complex of WA with Hsp90
(Figure 7) suggests the stability of WA even in complex
with Hsp90 alone. However a larger binding energy
Figure 4 Interactions of docked withaferin A with Hsp90
receptor. The docked withaferin A does not interact with any of
the Cdc37 interacting residues of Hsp90.
Table 2 Clustering results obtained from docking of withaferin A into Hsp90/Cdc37 complex
Receptor No. of
AutoDockclusters
a, b
Cluster
rank
b
No. of structuresin the
cluster
Lowest binding energy of
cluster
Energy range within
cluster
1 3 -13.95 -13.95 to -10.18
Hsp90/Cdc37
complex
2 (10) 2 7 -13.58 -13.58 to -10.11
aNumber of GA runs are shown in parentheses.
bClustering is done with RMS tolerance of 5.0 Å.
Figure 5 H-bonding interactions present in the docked
complex of withaferin A with active Hsp90/Cdc37 complex
using flexible docking. Polar hydroxyl terminal group of withaferin
A captivates amino group of Gln 208 of Cdc37 to form H-bond with
itself, thus disrupting the earlier present Gln 208 - Ser 113H-bond.
WA also disrupts the H-bond between Gln 133-Arg 166 by forming
H-bond with Arg 166 of Cdc37. WA also forms H-bonds with Asp
54 and Asp 106 of Hsp90.
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Page 9 of 13obtained for Hsp90/Cdc37/WA complex along with the
possibility of Hsp90/Cdc37 active complex formation
even in WA complexed Hsp90 substantially merits the
WA binding to the association complex in comparison
to segregated Hsp90 binding. This supports the hypoth-
esis that WA is quite a probable and a worth small
molecule for targeting/inhibiting the chaperone/co-
chaperone association complex. The simulation length
used in this study was long enough to allow rearrange-
ment of side chains of the native as well as the drug
complexed receptors to find their most stable binding
mode. In conclusion, the present MD simulations made
clear the dynamic structural stability of Hsp90/Cdc37 in
complex with the drug WA, together with the inhibitory
mechanism. These results would be valuable for further
designing non-covalent type inhibitors with high specifi-
city and potent activity by alternatively targeting the
Hsp90 signalling pathway in contrast to the classic
Hsp90 inhibition involving blockage of ATP binding.
Conclusions
The molecular chaperone Hsp90 has been a promising
target for cancer therapy. Cancer is a disease marked by
genetic instability. Thus specific inhibition of individual
proteins or signalling pathways holds a great potential
for subversion of this genetic plasticity of cancers. This
study is a step forward in this direction. Our computa-
tional analysis provided a rationalization to the ability of
naturally occurring WA to alter the chaperone signalling
pathway. The large value of binding energy involved in
binding of WA to the active Hsp90/Cdc37 complex con-
solidates the thermodynamic stability of the binding.
Our docking results obtained substantiate the hypothesis
that WA has the potential to inhibit the association of
Figure 6 (A) Plot of root mean square deviation (RMSD) of Ca of Hsp90/Cdc37 (protein) and Hsp90/Cdc37/WA (complex). RMSDs were
calculated using the initial structures as templates. For protein (red) the reference is the PDB structure and for complex (blue) the reference is
the initial docked structure. The trajectories were captured every 2.5 ps until the simulation time reached 4000 ps. (B) Plot of total energy of
Hsp90/Cdc37 and Hsp90/Cdc37/WA (complex) The energy trajectories of both the protein (red) and the complex (blue) are stable over the
entire length of simulation time.
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Page 10 of 13chaperone (Hsp90) to its co-chaperone (Cdc37) by dis-
rupting the stability of attachment of Hsp90 to Cdc37.
Conclusively our results strongly suggest that withaferin
A is a potent anticancer agent as ascertained by its
potent Hsp90-client modulating capability.
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